Related Experiment Video
Updated: Aug 22, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Antipsychotic drugs and risk of type 2 diabetes: an evidence-based approach
Cesario Bellantuono1, Luigi Tentoni, Pietro Donda
1Psychopharmacology Unit, Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Policlinico GB Rossi, Piazzale L. Scuro, 37134 Verona, Italy. cesario.bellantuono@univr.it
Objective:
To review studies conducted to evaluate the risk of type 2 diabetes in patients treated with different antipsychotic drugs (AP).
Methods:
a MEDLINE search (January 1985-February 2003) was conducted to establish the potential relationship between the exposure to AP (conventional and second generation) and the development of type 2 diabetes. Studies were classified according to their experimental design as prospective and retrospective (incidence and prevalence based).
Results:
Twenty-one studies were selected: nine prospective and eleven retrospective.
Data Synthesis And Conclusions:
Patients with schizophrenia treated with different AP have an increased risk of developing type 2 diabetes compared with the general population. The data so far available, however, do not establish whether the increasing risk of developing diabetes is a function of the schizophrenia itself or is induced by the antipsychotic treatment. A number of methodological flaws in the study design and data collection do not allow conclusions to be drawn on the risk between patients treated with conventional drugs versus those treated with new ones.
Related Concept Videos
Psychosis and Antipsychotic Drugs: Overview
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes I: Introduction
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Antipsychotic Drugs: Typical and Atypical Agents
Psychosis: Goals of Pharmacotherapy